The Effect of High-concentration Insulin Glarigine on the Quality of Life of Patients with Type 2 Diabetes Mellitus: A Pre-post Study (HIGH-QOL STUDY)

  • Murata Takashi
    Diabetes Center, National Hospital Organization Kyoto Medical Center, Japan
  • Tone Atsuhito
    Diabetes Center, Okayama University Hospital, Japan
  • Kouyama Ryuji
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Tsuchiura Kyodo General Hospital, Japan
  • Kamiuchi Kenji
    Division of Diabetes, Department of Internal Medicine, Aiseikai Yamashina Hospital, Japan
  • Narasaki Kohshi
    Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Tottori Prefectural Central Hospital, Japan
  • Tsuruo Miho
    Terasawa Hospital, Japan
  • Watanabe Tomokazu
    Diabetes Center, National Hospital Organization Kyoto Medical Center, Japan
  • Kawashima Satoshi
    Kanda Naika Clinic, Japan
  • Kato Ken
    Diabetes Center, National Hospital Organization Osaka National Hospital, Japan
  • Sawaki Hideaki
    Sawaki Internal Medicine and Diabetes Clinic, Japan
  • Osawa Kensou
    Osawa Naika Clinic, Japan
  • Kimura Moritsugu
    Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Japan
  • Toyoda Masao
    Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Japan
  • Suganuma Akiko
    Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan
  • Sakane Naoki
    Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan

Abstract

<p>Objective We compared the pain accompanying the injection of high-concentration (300 units/mL) insulin glargine (U300G) with that accompanying the injection of conventional (100 units/mL) insulin glargine (U100G). </p><p>Methods U100G was switched to U300G at basically the same dosage. Visual analog scales were used to assess the quality of life (QOL). The primary outcome was the change in the pain accompanying injections in those using ≥30 units of U100G compared with those using <30 units at baseline. Standardized mean differences (Cohen's d) were used to measure the effect size. </p><p>Patients Adult patients with type 2 diabetes mellitus using U100G. </p><p>Results One hundred and eight patients were recruited. The numbers of patients who used U100G at ≥30 units, 20 to <30 units, 10 to <20 units, and <10 units were 13, 14, 34, and 47, respectively. The improvement in the pain score was not significant for ≥30 units compared with <30 units (-50.3±24.0 vs. -40.4±28.5, p=0.25, d=0.38), but a significant difference was observed for ≥20 units compared with <20 units (-50.8±22.7 vs. -38.4±29.1, p=0.03, d=0.48), as well as for ≥10 units compared with <10 units (-48.1±25.0 vs. -33.0±29.7, p<0.01, d=0.56). When all patients were analyzed together, significant improvements in the pain score (-41.5±28.0, p<0.01), ease of use score (-37.5±32.2, p<0.01), force needed to inject score (-46.5±28.6, p<0.01), and preference for U300G compared with U100G score (-45.8±33.1, p<0.01) were observed. </p><p>Conclusion There is possibility that switching from U100G to U300G might be associated with better QOL for patients who require insulin glargine injections. To prove this hypothesis, a randomized controlled trial (preferably double-blinded) will be required in the future. </p>

Journal

  • Internal Medicine

    Internal Medicine 58 (20), 2943-2948, 2019-10-15

    The Japanese Society of Internal Medicine

References(6)*help

See more

Related Projects

See more

Details

Report a problem

Back to top